NCT02476851

Brief Summary

This study evaluates whether whole blood transferred through the new POLFA needle assembly meets supernatant hemoglobin acceptability standards.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

June 11, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 19, 2015

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
6.7 years until next milestone

Results Posted

Study results publicly available

April 29, 2022

Completed
Last Updated

April 29, 2022

Status Verified

April 1, 2022

Enrollment Period

1 month

First QC Date

June 11, 2015

Results QC Date

November 26, 2021

Last Update Submit

April 25, 2022

Conditions

Keywords

Blood DonationWhole Blood

Outcome Measures

Primary Outcomes (1)

  • Plasma Supernatant Hemoglobin

    To determine whether whole blood transferred to a Vacutainer® through the POLFA needle will have supernatant hemoglobin levels \<100 mg/dL within a 95% CI and 95% reliability. The average hemoglobin levels in the blood collected through each assembly is presented.

    Following a one-time whole blood donation, samples were measured within 1 month of donation.

Study Arms (2)

POLFA (Experimental Needle Assembly) first, then Kawasumi (Control Needle Assembly)

OTHER

Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or "INA") has a supernatant hemoglobin within the acceptable range of \< 100mg/dL. Each subject receives the same intervention (Standard of Care blood draw) and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Device: POLFA (Needle Assembly)Device: Kawasumi (Needle Assembly)

Kawasumi (Control Needle Assembly) first, then POLFA (Experimental Needle Assembly)

OTHER

Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or "INA") has a supernatant hemoglobin within the acceptable range of \< 100mg/dL. Each subject receives the same intervention (Standard of Care blood draw) and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Device: POLFA (Needle Assembly)Device: Kawasumi (Needle Assembly)

Interventions

Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Kawasumi (Control Needle Assembly) first, then POLFA (Experimental Needle Assembly)POLFA (Experimental Needle Assembly) first, then Kawasumi (Control Needle Assembly)

Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Kawasumi (Control Needle Assembly) first, then POLFA (Experimental Needle Assembly)POLFA (Experimental Needle Assembly) first, then Kawasumi (Control Needle Assembly)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Haemonetics

Braintree, Massachusetts, 02184, United States

Location

Hoxworth Blood Center

Cincinnati, Ohio, 45267, United States

Location

American Red Cross Mid-Atlantic Region Blood Services

Norfolk, Virginia, 23507, United States

Location

Results Point of Contact

Title
Jan Hartmann, MD
Organization
Haemonetics Corporation

Study Officials

  • Lou Ann Maes, MD

    American Red Cross Mid-Atlantic Region

    PRINCIPAL INVESTIGATOR
  • Jose Cancelas, MD

    Hoxworth Blood Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 11, 2015

First Posted

June 19, 2015

Study Start

June 1, 2015

Primary Completion

July 1, 2015

Study Completion

September 1, 2015

Last Updated

April 29, 2022

Results First Posted

April 29, 2022

Record last verified: 2022-04

Locations